AVIR

3.9600.76%
BG

Barbara G. Duncan

Independent Director

Ms. Barbara G. Duncan, M.B.A. is Chairman & Non-Executive Director of PhoreMost Limited since June 2025. She is a Director of Convergent Therapeutics, Inc. from December 2024. She serves as Independent Director of Halozyme Therapeutics, Inc. since February 3, 2023. She had been Chairperson of the Board at Fusion Pharmaceuticals Inc. since November 2020 until May 2024. She serves as Director at Halozyme, Inc. She serves as Independent Director at Versanis Bio, Inc. since July 2022. She has been Independent Director of Ovid Therapeutics Inc. since June 14, 2017. She has been an Independent Director of Atea Pharmaceuticals, Inc. since October 2020. She served as a Director of Innoviva, Inc. from November 18, 2016 to April 24, 2018. She served as a Director of Immunomedics, Inc. since March 7, 2019 until October 23, 2020. She served as the Chief Accounting Officer of Intercept Pharmaceuticals, Inc. from July 1, 2016 to September 30, 2016. She served as the Chief Financial Officer and Treasurer of Intercept Pharmaceuticals, Inc. from May 2009 to June 2016. She served as Secretary of Intercept Pharmaceuticals, Inc. since May 2009 through June 2016. Prior to Intercept, She held various senior leadership roles of increasing responsibility at DOV Pharmaceutical, Inc. She served as the Chief Financial Officer and Treasurer of DOV Pharmaceutical Inc. since August 2001 until April 2009 and its Chief Executive Officer since February 2, 2007 until April 2009. She has extensive financial leadership experience, with some of those years in management roles within the pharmaceutical industry. She served as the President and Principal Accounting Officer of DOV Pharmaceutical, Inc. until February 2, 2007 and its Senior Vice President of Finance and Treasurer since August 2001 and also served as its Vice President of Finance. She was chief executive officer prior to DOV’s sale to Euthymics Bioscience Inc. in 2010. She served as Vice President of Corporate Finance Division at Lehman Brothers Inc. from August 1998 to August 2001, where she provided Financial Advisory Services primarily to Companies in Life Sciences and General Industrial Industries. From September 1994 to August 1998, she served as an Associate and Director in Corporate Finance Group at SBC Warburg Dillon Read, Inc., where she focused primarily on Structuring Mergers, Divestitures and Financings for companies in the Life Sciences and General Industrial Industries. She served at PepsiCo, Inc. from 1989 to 1992 in its International Audit division and served as a Certified Public Accountant in the Audit Division of Deloitte & Touche from 1986 to 1989. She had been an Independent Non-Executive Director of Adaptimmune Therapeutics plc since June 23, 2016 until May 2023. She served as a Director at ObsEva SA since November 2016 until May 28, 2021. She had been an Independent Director of Aevi Genomic Medicines, Inc. since June 2015 until January 2020. She had been an Independent Director of Jounce Therapeutics, Inc. since June 2016 until May 2023. She serves as a Member of the Board of Directors at Edgemont Pharmaceuticals, LLC. She served as a Director of DOV Pharmaceutical Inc. since July 2005. She received her Bachelor of Business Administration/BS from Louisiana State University in 1985, B.A. from Louisiana State University and her M.B.A. from the Wharton School, University of Pennsylvania in 1994.

Positions